Celldex Income Tax Expense from 2010 to 2024

CLDX Stock  USD 26.51  0.11  0.42%   
Celldex Therapeutics Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense will likely drop to about 1.6 M in 2024. During the period from 2010 to 2024, Celldex Therapeutics Income Tax Expense regression line of annual values had r-squared of  0.06 and arithmetic mean of (1,973,669). View All Fundamentals
 
Income Tax Expense  
First Reported
1990-03-31
Previous Quarter
13.4 M
Current Value
731.7 K
Quarterly Volatility
M
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 5.8 M or Selling General Administrative of 29.4 M, as well as many indicators such as Price To Sales Ratio of 293, Dividend Yield of 0.0 or PTB Ratio of 3.62. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Latest Celldex Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Celldex Therapeutics over the last few years. It is Celldex Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celldex Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Pretty Stable
   Income Tax Expense   
       Timeline  

Celldex Income Tax Expense Regression Statistics

Arithmetic Mean(1,973,669)
Geometric Mean1,534,611
Coefficient Of Variation(372.34)
Mean Deviation4,247,110
Median(530,000)
Standard Deviation7,348,744
Sample Variance54T
Range34.7M
R-Value0.24
Mean Square Error54.7T
R-Squared0.06
Significance0.38
Slope398,538
Total Sum of Squares756.1T

Celldex Income Tax Expense History

20241.6 M
20232.8 M
202210.5 M
2021-227 K
2020-1.2 M
2019-506 K
2018-765 K

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense2.8 M1.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.